DSB1559

DSB1559 is a novel, highly selective small molecule inhibitor of poly (ADP-ribose) polymerase 1 (PARP1), developed by Duke Street Bio. It demonstrates superior selectivity for PARP1 over other PARP family members and has shown greater efficacy compared to olaparib and AZD5305 in preclinical models, particularly in BRCA1-associated triple negative breast cancer. The drug is being investigated for its potential as an anti-cancer agent, with a focus on tumors exhibiting homologous recombination deficiency such as those associated with BRCA mutations. Its mechanism involves inhibition of PARP1 activity, which impairs DNA repair in cancer cells and leads to cell death[1][2][3][4][7].